Encelto (revakinagene taroretcel-lwey) / Neurotech Pharma - LARVOL DELTA

Macular telangiectasia type 2: An update. (PubMed, J Int Med Res) - "These include serine supplementation, fenofibrate to reduce 1-deoxysphingolipid production, and gene replacement therapy. In addition, growing evidence suggests that mitochondrial dysfunction and impaired cellular energy metabolism contribute to disease pathogenesis and warrant further investigation as potential therapeutic targets."

Journal • Review • CNS Disorders • Metabolic Disorders • Ophthalmology

Association between AREDS/2 supplementation and structural and functional progression in macular telangiectasia type 2. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "AREDS/2 supplementation was not associated with meaningful differences in structural or functional MacTel progression over a 24-month period. These findings do not provide evidence that routine AREDS/2 supplementation slows EZ area loss or preserves visual function in this population."

Journal • Diabetes • Metabolic Disorders • Ophthalmology

Pooled Analyses of Anatomic and Visual Function Data of Revakinagene Taroretcel-lwey in Participants with Macular Telangiectasia Type 2. (PubMed, Ophthalmol Retina) - "In this pooled analysis, revakinagene taroretcel-lwey reduced the rate of MacTel disease progression and preserved visual function over 24 months as shown by reductions in the rate of EZ area loss, reading speed loss, and aggregate retinal sensitivity loss."

Clinical • Journal • Ophthalmology

PRICE ANALYSIS OF GENE THERAPIES AUTHORIZED BY THE U.S. FOOD AND DRUG ADMINISTRATION (ISPOR 2026) - "The inflation-adjusted WAC (adj-WAC) ranged from $253,121 (revakinagene taroretcel) to $4,395,213 (atidarsagene autotemcel)...Tisagenlecleucel had different prices for two indications and onasemnogene abeparvovec for two routes of administration/patient populations... When adjusted for inflation, prices remained relatively constant over time. Prices varied depending on therapeutic class, patient population, and duration of therapy. Gene therapies had similar WAC and ASP."

Gene therapy • Gene Therapies

Neuroprotection in Glaucoma: Dose-Dependent Effects of Single and Dual NT-501 Ciliary Neurotrophic Factor Implants in a Randomized, Multicenter, Masked, Sham-Controlled Phase II Trial (ARVO 2026) - P2 | "Conclusions CNTF-secreting implants were well tolerated and conferred IOP-independent RNFL neuroenhancement, with dose-dependent visual field neuroprotection compared with sham. These findings support CNTF therapy as a promising neuroprotective treatment strategy for glaucoma."

Clinical • P2 data • Glaucoma • Ophthalmology

Impact of AREDS/2 Oral Supplementation on Macular Telangiectasia Type 2 Progression: A Retrospective Analysis of the NT-501 Phase 3 Trials (ARVO 2026) - "This analysis was limited by the small, imbalanced sample size in the AREDS group, which, despite robust adjustment for covariates, could affect the precision of the treatment effect estimate. The overall findings suggest limited impact of AREDS formulations on MacTel disease progression, highlighting the need for targeted therapies."

P3 data • Retrospective data • Ophthalmology

Long-term longitudinal changes in outer retinal hyperreflectivity and ellipsoid zone in macular telangiectasia type 2 and association with optical coherence tomography angiography flow (ARVO 2026) - "Conclusions Eyes that develop OCTA-detectable flow at any time exhibit faster EZ loss and distinct ORHR progression patterns, compared with eyes that remain flow-negative. ORHR volume and flow status may provide useful structural markers for monitoring long-term disease progression in MacTel."

Ophthalmology

Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation. (PubMed, Genes (Basel)) - "While gene-specific replacement therapies have achieved landmark success with voretigene neparvovec (Luxturna) for biallelic RPE65-associated retinal dystrophy, developing individual therapies for each genetic subtype remains impractical...Combination strategies simultaneously addressing multiple pathogenic pathways may offer synergistic benefits. Gene-agnostic approaches targeting neuroprotection and immunomodulation offer a therapeutic paradigm capable of benefiting patients across the spectrum of IRD genotypes, potentially transforming treatment for conditions where mutation-specific therapies remain unavailable."

Journal • Review • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Gene Therapies • Immunology • Inherited Retinal Dystrophy • Macular Degeneration • Ophthalmology • Retinal Disorders • BDNF

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants (clinicaltrials.gov) - P4 | N=285 | Recruiting | Sponsor: Neurotech Pharmaceuticals | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2030 ➔ Jan 2032 | Initiation date: Aug 2025 ➔ Nov 2025 | Trial primary completion date: Aug 2030 ➔ Jan 2032

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Ophthalmology

Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2. (PubMed, Ophthalmol Sci) - "Further studies are ongoing to investigate the long-term efficacy of NT-501 for treating MacTel. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • P1 data • Ophthalmology

Current State of the Neurotrophin-Based Pharmaceutics in the Treatment of Neurodegenerative Diseases and Neuroinflammation. (PubMed, Med Sci (Basel)) - "The study identified limitations and future prospects for neurotrophin-based pharmaceuticals. For future clinical trials, attention should be paid to the pharmacogenetic profiles of the patients and the evaluation of the inflammatory status of the disease. Novel plasma biomarkers of the effectiveness are needed as well as TSPO-PET imaging. Drug delivery systems remain insufficient; therefore, efforts should focus on inducing endogenous neurotrophin production and developing highly selective agonists and antagonists of neurotrophin receptors. It is crucial to establish a favorable premorbid background before neurotrophin therapy to minimize immunoresistance."

Journal • Review • Alzheimer's Disease • CNS Disorders • Gene Therapies • Inflammation • Mental Retardation • Movement Disorders • Neuralgia • Ophthalmology • Pain • Parkinson's Disease • Psychiatry

Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease. (PubMed, Adv Drug Deliv Rev) - "This comprehensive review examines the latest advancements of these combination platforms, including refillable implants (e.g., SUSVIMO®), encapsulated cell technology (e.g., ENCELTO™), and recombinant adeno-associated virus (rAAV) vectors (e.g., LUXTURNA®)...However, substantial hurdles, such as instability caused by material-biologics interactions, potential risks during the sterilization and manufacturing processes, safety risks, and the evolving regulatory landscape, still need to be addressed. Achieving a balance between the stability of biologics and advanced device design, enhancing long-term safety, and developing responsive smart systems with real-time monitoring and feedback capabilities remain crucial for the advancement of next-generation ophthalmic therapies."

Journal • Review • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders

LONG-TERM PROGRESSION OF ELLIPSOID ZONE LOSS AND ASSOCIATED FEATURES ON OPTICAL COHERENCE TOMOGRAPHY IN MACULAR TELANGIECTASIA TYPE 2. (PubMed, Ophthalmology) - "EZ loss in MacTel follows a characteristic sigmoid trajectory, with distinct morphologic types predicting progression velocity. While Pattern 1 lesions remain stable for longer periods, Pattern 2 and 3 indicate fast progression. These findings provide structural benchmarks that may help guide clinical management and treatment timing, particularly in light of emerging implant-based therapies such as Revakinagene taroretcel Encelto®."

Journal • Ophthalmology

Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Stanford University | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Aug 2026

Enrollment closed • Trial completion date • Glaucoma • Ophthalmology

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration (clinicaltrials.gov) - P2 | N=54 | Active, not recruiting | Sponsor: Stanford University | Trial completion date: Dec 2025 ➔ Aug 2026

Trial completion date • Glaucoma • Ophthalmology

Clinical histopathology and pathogenesis of macular telangiectasia type 2. (PubMed, Prog Retin Eye Res) - "We also review current neuroprotective strategies and provide targeted recommendations for future therapeutic development and histopathologic research. The conceptual framework developed in this work -grounded in rigorous analysis of the most consistent and methodologically validated histopathologic findings, and interpretation of their mechanistic context- may serve as a model for deciphering rare retinal diseases and for generating focused, hypothesis-driven questions to guide future investigation."

Journal • Review • CNS Disorders • Ophthalmology • Retinal Disorders

Conjunctival histopathological changes associated with netarsudil 0.02. (PubMed, Eye (Lond)) - "Conjunctiva treated with netarsudil may be more likely to demonstrate inflammation compared to those treated with other combinations of glaucoma medications. These findings may have surgical implications and additional studies correlating clinical outcomes are required."

Journal • Glaucoma • Inflammation • Ophthalmology

Updated Surgical Technique for Implantation of Revakinagene Taroretcel. (PubMed, Retina) - "The described surgical implantation technique was developed using learnings from the associated phase 2 and 3 trials and implemented to maximize the likelihood of long-term capsule stability and minimize the risk of adverse events including device extrusion."

Journal • Ophthalmology

Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2. (PubMed, NEJM Evid) - P3 | "NT-501 for MacTel resulted in statistically significantly reduced EZA loss compared with sham procedures. (Funded by Neurotech Pharmaceuticals; ClinicalTrials.gov numbers, NCT03316300 and NCT03319849.)."

Clinical • Journal • Ophthalmology

Long-Term Durability of Ciliary Neurotrophic Factor-Releasing Revakinagene Taroretcel-lwey in Individuals With Retinal Degenerative Disorders. (PubMed, Invest Ophthalmol Vis Sci) - P1, P2, P3 | "There was no evidence of an immunological reaction to CNTF or the NTC-201-6A cells. This retrospective analysis suggests that a single, intraocular administration of revakinagene taroretcel-lwey provides sustained, bioactive CNTF for durations exceeding a decade, potentially providing a long-term treatment option for chronic retinal degenerative diseases."

Journal • Retrospective data

Surgical Explantation of Revakinagene Taroretcel Capsule Due to Non-Clearing Vitreous Hemorrhage Secondary to Fixation Loop Extrusion. (PubMed, Am J Ophthalmol) - No abstract available

Journal • Hematological Disorders • Ophthalmology • Retinal Disorders

Revakinagene Taroretcel: First Approval. (PubMed, Mol Diagn Ther) - "Revakinagene taroretcel has been granted Orphan Drug Designation for retinitis pigmentosa and Fast Track Designation for retinitis pigmentosa and dry age-related macular degeneration in the USA. This article summarises the milestones in the development of revakinagene taroretcel leading to this first approval for the treatment of adults with idiopathic MacTel type 2 in the USA."

Journal • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Beyond the injection: delivery systems reshaping retinal disease management. (PubMed, Expert Opin Pharmacother) - "Specific innovations discussed include the ranibizumab port delivery system, EYP-1901 (Duravyu, vorolanib implant), KSI-301 (tarcocimab tedromer), KSI-501, OTX-TKI (Axpaxli, axitinib implant), 4D-150, revakinagene taroretcel-lwey (Encelto, NT-501, encapsulated cell therapy), Xipere (triamcinolone acetonide injectable suspension), AU-011 (belzupacap sarotalocan targeted delivery), ABBV-RGX-314, elamipretide, and OCS-01 (high concentration dexamethasone)...Challenges include overcoming the blood-retinal barrier, surgical complications with implantable devices, and ensuring patient adherence. Advances in smart delivery systems, drug formulations, and predictive models, alongside interdisciplinary collaboration, will be crucial in achieving personalized, effective, and sustainable retinal therapies."

Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders

NT-501 Capsule Stability and Encapsulated Cell Technology Platform Capabilities (ASGCT 2025) - "The simulated in vivo stability study supports that the NT-501 capsule remains integral and the capsule materials are stable for at least two years. Additionally, modifications can be made to the ECT capsule to alter the delivery levels or targets of therapeutics making it a versatile long term delivery platform for intraocular diseases. Disease Focus of Abstract:Ophthalmic Diseases"

Ophthalmology

Sustained Drug Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology: NT-501 Implants: (ASGCT 2025) - "Neurotech's ECT was developed to overcome the challenge of long-term therapeutic delivery to the retina. NT-501 consists of an encapsulated cell line that has been genetically engineered to produce a novel secreted form of human CNTF. Extensive characterization was conducted across product shelf life, stability, and on explanted devices which were implanted for up to 14.5 years."

Ophthalmology